Preparation of antibody against ANKRD22 and its expression in colorectal cancer
10.19485/j.cnki.issn2096-5087.2019.03.004
- VernacularTitle:ANKRD22检测抗体制备及其在结直肠癌中的表达
- Author:
Yunhua LIN
1
,
2
;
Jingwen LIU
;
Saisai YANG
;
Xiyong LIU
;
Hongping WANG
Author Information
1. First People'
2. s Hospital of Pinghu
- Publication Type:Journal Article
- Keywords:
Colorectal cancer，ANKRD22，Expression，Monoclonal antibody，Immunohistochemical staining
- From:
Journal of Preventive Medicine
2019;31(3):231-235
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To prepare the monoclonal antibody against ankyrin repeat domain 22（ANKRD22）and to investigate its expression in colorectal cancer tissues.
Methods :The recombinant human ANKRD22 was expressed through E. coli and pET-42a and then used to immunize Balb/c mice after purification. Anti-human ANKRD22 specific monoclonal antibodies were selected by Western blotting with 293T cell lysate highly expressing ANKRD22 as antigen. The expression of ANKRD22 in the tissue microarrays of 112 patients with colorectal cancer was detected by immunohistochemical staining.
Results :Four specific monoclonal antibodies against human ANKRD22 were screened out of 93 hybridoma cells,which reacted well with natural human ANKRD22. ANKRD22 was mainly distributed in the cytoplasm of colorectal cancer cells. In 112 cases of colorectal cancer,94 cases were detected positive for ANKRD22 expression,with the positive rate of 83.93%. The expression of ANKRD22 was statistically correlated with the expression of p53 and β-catenin（P<0.05）,but not with age,sex,location of tumors,AJCC stage,Dukes stage,degree of differentiation,lymph node metastasis and mismatch repair gene expression（P>0.05）.
Conclusion :The expression level of ANKRD22 was high in colorectal cancer. ANKRD22 might be involved in the carcinogenesis of colorectal epithelium and be a potential diagnostic marker.
- Full text:ANKRD22检测抗体制备及其在结直肠癌中的表达.pdf
